Practices
Industries
Jurisdictions

Lidings Team Wins a Precedent-Setting Dispute on The Cancellation of a Drug Registration Due to Inaccurate Information in The Drug Dossier

28 November 2024

Lidings’ Intellectual Property practice team succeeded in obtaining cancellation of registration of a drug in a dispute against the holder of the marketing authorisation (MA) due to the fact that during the process of registration of a generic drug product the Ministry of Health of Russia received false information from the holder of the MA.

Lidings Ran a Roundtable on Launch of Medicines and Pharmaceutical Substances in Russian and Indian Markets in Delhi

11 November 2024

On November 7, 2024, Lidings held a round table discussion " Launch of Medicines and Pharmaceutical Substances in Russian and Indian Markets" as part of the business program of the Forum "Under One Sun: Russia-India. Business and Culture ", which took place in Delhi, November 6 - 8, 2024.

Highlights of the event in our overview.

Lidings Holds a Round Table on Launch of Medicines and Pharmaceutical Substances in the Russian Market in Delhi

06-08 November 2024

On 6-8 November 2024 the international forum “Under One Sun: Russia-India. Business and Cultur” will take place in Delhi, India withing the 100th anniversary of the Russian Association for International Cooperation. The event is organized on the initiative of the Ministry of Foreign Affairs of the Russian Federation and the Trade Mission in India with the support of Lidings as a co-organizer of the business discussion.

During the forum on November 7 Lidings will hold a special round table “Launch of Medicines and Pharmaceutical Substances in Russian and Indian Markets” moderated by Lidings’ partner Boris Malakhov and counsel Natalya Thotahewage.

Significant Turnaround in Russian Antitrust Practice of Protecting the Exclusivity of Drugs

29 October 2024

Despite the fact that the issue of intellectual property rights turnover is included in the perimeter of antimonopoly regulation, until recently the Russian Antitrust Agency took rather an observant position.

The regulator's position was that the issue of patent infringement is a private legal dispute between original and generic manufacturers, which should not affect the turnover of drugs, particularly the execution of contracts based on the results of public procurement. Only in isolated cases the Russian Antitrust Agency has established the fact of patent infringement and issued a corresponding order on the inadmissibility of anti-competitive practices.

Now the reverse trend has clearly emerged.

More in our update.


The Procedure for Obtaining by Ministry of Industry and Trade Information Constituting a Trade Secret of Pharmaceutical Manufacturers Has Been Changed

30 September 2024

On 1 September 2024, a joint order of the Ministry of Industry and Trade No. 3554 and the Ministry of Health No. 406n dated 7 August 2024 (hereinafter referred to as the “Order”) entered into force, approving a new procedure for providing the Ministry of Industry and Trade with information on medicines necessary for the purposes of licensing their production and inspecting the subjects of their circulation for compliance the requirements of good manufacturing practice. The Order replaced the previously existing procedure for interdepartmental interaction between the Ministry of Health and the Ministry of Industry and Trade.

Changes In Regulatory Framework for Dietary Supplements in Russia: What Is to Be Expected?

24 July 2024

On 9 July 2024, the State Duma passed Bill No. 638771-8 “On Introduction of the Draft Federal Law ’On Amendments to Certain Legislative Acts of the Russian Federation’” (the “Bill”) in first reading, which focuses on changes in the regulatory regime for the circulation of dietary supplements in Russia.

The proposed amendments would introduce significant changes affecting the circulation of dietary supplements and, to a certain extent, bringing it closer to the regime established for pharmaceuticals and medical devices.